Ivabradine Shows Promise as Tx for Hyperadrenergic POTS

Further study needed in other POTS subtypes In patients with hyperadrenergic postural orthostatic tachycardia syndrome (POTS), one month of treatment with ivabradine brought about significant improvements in several parameters, including heart rate, quality of life (QOL), and plasma norepinephrine (NE) levels, according to results from a recent study published in the Journal of the American

Article: Postural orthostatic tachycardia syndrome (POTS): a

ivabradine study results · MUSINGS OF A DYSAUTONOMIAC

Karsten HEUSSER, Senior Physician Scientist

Karsten HEUSSER, Senior Physician Scientist

Ivabradine effects on COVID-19-associated postural orthostatic

Ivabradine for treatment of tachyarrhythmias in children and young

Frontiers Chronic Treatment with Ivabradine Does Not Affect

PDF) Cognitive Dysfunction in Postural Tachycardia Syndrome.

Postural Tachycardia Syndrome and COVID-19: Focus on Ivabradine

Acute hyperhidrosis and postural tachycardia in a COVID-19 patient

Postural Tachycardia Syndrome: Beyond Orthostatic Intolerance

Postural orthostatic tachycardia syndrome (POTS): State of the

Symptom presentation by phenotype of postural orthostatic

Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1 - ScienceDirect

Cracking the Code of Dysautonomia: POTS, Orthostatic Hypotension, and Heart Health